Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

C. diff. antibiotic shows high activity in vitro
August 2017
SHARING OPTIONS:

OXFORD, U.K.—Summit Therapeutics plc shared preclinical data regarding ridinilazole, its novel, highly selective antibiotic for Clostridium difficile infection (CDI), at the ASM Microbe 2017 meeting held in June. The data was shared in two poster presentations titled “In-vitro Activity of Ridinilazole and Comparators against Isolates of Clostridium difficile Obtained from Stools of Patients as Part of US surveillance in 2014” and “In vitro Selection of Clostridium difficile Resistance Mutants Exposed to Ridinilazole.”
 
When tested against 200 clinical isolate of C. diff., ridinilazole was found to be very active against all isolates, and based on MIC90 (minimum inhibition concentration) of 0.25 mg/mL, proved to be more potent than vancomycin and metronidazole. It also maintained activity against isolates that have proven resistant to common antibiotics. In studying resistance development, a low-level, stable ridinilazole mutant resistant strain was developed after several sub-MIC passages, which will be used in further testing.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.